Beatrice L. Brown joins Ethics Talk to discuss her article, coauthored with Dr Aaron S Kesselheim: "How Should Clinicians and Organizations Assess Risks and Benefits of First-in-Human Implantation of Investigational Devices?"
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
The high prevalence of violence experienced by Native American women and femme-identifying individuals requires clinicians and staff to better understand social determinants of violence.
AMA J Ethics. 2020;22(10):E888-892. doi:
10.1001/amajethics.2020.888.
Sara Silbert, MD, Gregory A. Yanik, MD, and Andrew G. Shuman, MD
“Living” drugs target specific B-cell malignancy tumor antigens, but cost hundreds of thousands of dollars. Value analysis can help determine whether to offer these customized drugs.
AMA J Ethics. 2019;21(10):E844-851. doi:
10.1001/amajethics.2019.844.
Sara Scarlet, MD and Selwyn O. Rogers, Jr., MD, MPH
Pervasive and recurrent gun violence compels health care organizations to integrate violence prevention, intervention, and recidivism reduction as critical dimensions of good trauma care.
AMA J Ethics. 2018;20(5):483-491. doi:
10.1001/journalofethics.2018.20.5.msoc2-1805.
Hanni Stoklosa, MD, MPH, Marti MacGibbon, CADC-II, ACRPS, and Joseph Stoklosa, MD
Clinicians diagnosing and treating potentially trafficked patients with co-occurring addiction and mental illness should guard against expressing negative biases.
AMA J Ethics. 2017;19(1):23-24. doi:
10.1001/journalofethics.2017.19.1.ecas3-1701.
Should old folks who have lived their lives be allowed to place a huge economic burden on the young by using a disproportionate amount of limited Medicare resources for medical care?